24.10.2017

THE EASL INTERNATIONAL LIVER FOUNDATION JOINED FORCES FOR THE FIRST TIME WITH THE SAUDI ASSOCIATION FOR THE STUDY OF LIVER DISEASES AND TRANSPLANTATION SASLT

The EASL International Liver Foundation joined forces for the first time with the Saudi Association for the Study of Liver Diseases and Transplantation SASLT in a common educational initiative which took place in Jeddah, Kingdom Saudi Arabia on September 29th, 2017. The meeting produced lively interactive scientific discussions between experts from Saudi Arabia and Europe on a variety of liver diseases.

Learn more

24.10.2017

THE EASL INTERNATIONAL LIVER FOUNDATION TO HOLD ITS FIRST INTERNATIONAL CONSULTATIVE MEETING ON ELIMINATION OF VIRAL HEPATITIS IN PATIENTS WITH CHRONIC KIDNEY DISEASE IN NEW ORLEANS, LA USA

The EASL International Liver Foundation to hold its first international consultative meeting on elimination of viral hepatitis in patients with chronic kidney disease in New Orleans on November 1st 2017. The meeting is the result of a strategic partnership between the Foundation and the European Renal Association

Learn more

24.10.2017

THE EASL INTERNATIONAL LIVER FOUNDATION POISED TO INITIATE A NEW COLLABORATION WITH THE EUROPEAN HAEMOPHILIA CONSORTIUM

A new collaboration between the EASL International Liver Foundation and the European Haemophilia Consortium is expected to take place over the coming months. The two organisations held a consultative meeting in Vilnius, Lithuania on Friday, October 6th, 2017.

Learn more

24.10.2017

THE THALASSEMIA INTERNATIONAL FEDERATION AND THE EASL INTERNATIONAL LIVER FOUNDATION TO HOLD FIRST CONSULTATION MEETING IN THESSALONIKI, GREECE

The Thalassemia International Federation and the EASL International Liver Foundation are set to hold the first consultative meeting in Thessaloniki, Greece on November 17th 2017 on viral hepatitis elimination.

Learn more

24.10.2017

FIRST INVESTIGATOR MEETING ON NAFLD POLICY REVIEW TO TAKE PLACE IN ROME ON NOVEMBER 10TH 2017

The First investigator meeting for the NAFLD Policy Review will take place in Rome on November 10th 2017. The purpose of the study is to:

Learn more

24.10.2017

GILEAD SCIENCES INTERNATIONAL RESEARCH SCHOLARS PROGRAM IN LIVER DISEASE: The 2018 Program Now Open

The mission of the program is to support innovative scientific research that will advance knowledge in the field of liver disease and provide support for research career development.

Learn more

23.10.2017

ADDRESSING BILIARY DISEASES: THE CONTRIBUTION OF BILE DUCT ENGINEERING

Bile duct disease accounts for a third of adult and 70% of pediatric liver transplantations. Several of these disorders are widespread and affect the small branches of the intrahepatic bile ducts which are not amenable to surgical replacement or reconstruction.

Learn more

23.10.2017

IMMUNOTHERAPY OF LIVER CANCER: PRINCIPLES AND CHALLENGES

The story of drug development for hepatocellular carcinoma (HCC) has been disappointing in the past eight years with many drugs failing in phase III trials.

Learn more

23.10.2017

HOW TO IDENTIFY DRUGS WITH THE POTENTIAL TO HARM THE LIVER

Idiosyncratic drug-induced liver injury (DILI) is a rare diagnosis in clinical practice by far less common than other liver diseases such as viral hepatitis. However, data on DILI incidence in the general population are very limited. A main barrier to undertake these studies is the lack of a standard for DILI diagnosis so suspected cases should undergo a formal causality assessment process, which always result in some degree of uncertainty.

Learn more

23.10.2017

PLATELETS SHAPRONING LYMPHOCYTES TO ATTACK HEPATITIS B LIVER CELLS: DANGEROUS LIAISONS

The first evidence involving platelets in the pathogenesis of hepatitis B emerged from our laboratory over 10 years ago (1). Using mouse models of acute viral hepatitis (e.g. HBV replication-competent transgenic mice transferred with HBV-specific effector CD8+ T cells or wild-type mice infected with hepatotropic adenoviruses), we showed that platelets are detectable at sites of organ damage and their depletion reduces the number of intrahepatic HBV-specific CD8+ T cells – and the number of antigen-nonspecific inflammatory cells that these CD8+ T cells secondarily recruit into the liver – ameliorating disease severity

Learn more

23.10.2017

TREATMENT OF CHILDREN AND ADOLESCENTS IS ESSENTIAL TO FULFIL WHO’S ELIMINATION GOALS

The pediatric and adolescent population is often overlooked in surveys and the burden of disease is essentially unknown particularly in countries with high prevalence rates. It is imperative to determine the brunt of the disease in the pediatric population to fulfill the WHO’s global HCV elimination goals, also diagnose and cure children at an early age before adolescence and behaviors associated with high risk of transmission.

Learn more

23.10.2017

United States National Academies of Sciences, Engineering and Medicine Report on Elimination of Hepatitis B and C

In response to the World Health Organization’s (WHO) strategic goal to eliminate hepatitis B and C by 2030, the United States National Academies of Sciences, Engineering and Medicine (NASEM) convened and released two reports in 2016 and 2017 confirming the feasibility of reaching the goal set by WHO and the actions that would be needed to accomplish that goal.

Learn more
  • 1 of 3